• 【Exhibition & Presentation】Exhibiting and Presenting at BioJapan 2026

  2026-09-24 【Exhibition & Presentation】Exhibiting and Presenting at BioJapan 2026 TFBS Bioscience will be exhibiting at BioJapan 2026 in Yokohama, Japan, from October 7 to October 9, 2026. During the event, in addition to showcasing our latest CDMO and CRO solutions at our booth, we will also participate in the exhibitor presentation hosted by Mitsui Fudosan Co., Ltd. We look forward to connecting with industry partners and attendees at the exhibition. Learn more

• TFBS Bioscience Partners with Medigen Vaccine Biologics to Support Process Development for a Second-Generation Multivalent Enterovirus Vaccine

  2026-08-24 TFBS Bioscience Partners with Medigen Vaccine Biologics to Support Process Development for a Second-Generation Multivalent Enterovirus Vaccine TFBS Bioscience, Inc. (TWSE: 6939; Headquarters: New Taipei City, Taiwan; “TFBS”) today announced a new phase of collaboration with Medigen Vaccine Biologics Corporation (TWSE: 6547; “MVC”). Under this collaboration, TFBS will provide contract development and manufacturing organization (CDMO) services for MVC’s second-generation multivalent enterovirus vaccine. Learn more

• TFBS Bioscience and Japan Tissue Engineering Collaborate on Feasibility Study for Commercialization of Regenerative Medicine Products (Autologous Cultured Epidermis, etc.) in Taiwan ～Collaboration under the "FY2026 Healthcare Industry International Expansion Promotion Project Subsidy"～

  2026-08-21 TFBS Bioscience and Japan Tissue Engineering Collaborate on Feasibility Study for Commercialization of Regenerative Medicine Products (Autologous Cultured Epidermis, etc.) in Taiwan ～Collaboration under the "FY2026 Healthcare Industry International Expansion Promotion Project Subsidy"～ TFBS Bioscience, Inc. (Headquarters: New Taipei City, Taiwan; hereinafter "TFBS") and Japan Tissue Engineering Co., Ltd. (Headquarters: Gamagori City, Aichi Prefecture, Japan; hereinafter "J-TEC") have agreed to collaborate on a study regarding a study on the commercialization of J-TEC's regenerative medicine products (such as autologous cultured epidermis) currently marketed in Japan for the Taiwan market. Learn more

• TFBS Bioscience and Adara Bio Collaborate to Accelerate Development of AAV-based Gene Therapy

  2026-07-17 TFBS Bioscience and Adara Bio Collaborate to Accelerate Development of AAV-based Gene Therapy TFBS Bioscience, Inc. (Headquarters: New Taipei City, Taiwan; hereinafter “TFBS”), a leading viral vector CDMO and CRO service provider in Taiwan, and Adara Bio Pty Ltd (hereinafter “Adara Bio”), an Australian-based company, announce a collaboration agreement for adeno-associated virus (AAV) vector manufacturing at BIO Asia 2026 in Taipei. Under the partnership, Adara Bio, a biotechnology company focused on the development of next generation RNA medicines for inherited retinal diseases (IRDs), will leverage TFBS's expertise in contract development and manufacturing organisation (CDMO) services to support its preclinical and future clinical programs. Learn more

• TFBS Bioscience and QIMR Berghofer Sign MOU to Advance Global CGT Collaboration in Cell and Gene Therapy

  2026-05-28 TFBS Bioscience and QIMR Berghofer Sign MOU to Advance Global CGT Collaboration in Cell and Gene Therapy TFBS Bioscience, Inc. (Headquarters: New Taipei City, Taiwan; hereinafter “TFBS”) and QIMR Berghofer Medical Research Institute (Headquarters: Herston, Queensland, Australia; hereinafter “QIMR Berghofer”) jointly announced the signing of a Memorandum of Understanding (MOU) on April 29, 2026, establishing a strategic partnership in the field of cell and gene therapy (CGT). The collaboration aims to combine the expertise and resources of both organizations to advance the development of innovative therapies and expand international market opportunities. Learn more